Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.15134 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer.
Clin Cancer Res
January 2025
University Hospital Essen, Essen, Germany.
Antibodies targeting immune checkpoints, such as PD-1, PD-L1, or CTLA-4, have transformed the treatment of patients with lung cancers. Unprecedented rates of durable responses are achieved in an imperfectly characterized population of patients with metastatic disease. More recently, immune checkpoint inhibitors have been explored in patients with resectable non-small-cell lung cancers.
View Article and Find Full Text PDFA case of subcutaneous metastatic malignant melanoma of the left medial ankle: a case report and review of literature.
J Med Case Rep
December 2024
College of Medicine and Life Sciences, Division of Plastic and Reconstructive Surgery, University of Toledo, 3000 Arlington Ave, Toledo, OH, 43614, USA.
Background: Although rare, melanoma confined to the dermis or subcutaneous tissue without evidence of a primary cutaneous site should provoke consideration of melanoma of unknown primary. This diagnosis carries a favorable prognosis when compared with cutaneous metastatic melanoma. Several hypotheses have been proposed for how melanoma of unknown primary develops, two of which were considered in our patient case: (1) spontaneous regression of the primary tumor following metastasis or (2) the traumatic implantation of ectopic melanocytic cells in other tissues, such as the subcutaneous tissue.
View Article and Find Full Text PDFReal-world evidence of adjuvant immunotherapy in resected stage III and IV melanoma patients: CADIM trial final results. Experience from 2 tertiary referral centers.
Actas Dermosifiliogr
December 2024
Servicio de Oncología Médica, Hospital Clínico Universitario Virgen de la Arrixaca, Ciudad de Murcia, Spain; Instituto Murciano de Investigación Biosanitaria (IMIB), Spain.
Introduction: Clinical trials have validated the use of nivolumab and pembrolizumab as adjuvant therapies regarding relapse-free survival (RFS) in patients with resected stage III and IV melanoma. Evidence in real-world patients is currently limited.
Material And Method: The CADIM trial (Characterization of adjuvant immunotherapy in melanoma patients) recruited a total of 81 patients with resected stage III and IV melanoma on nivolumab or pembrolizumab as adjuvant therapy from February 2018 through December 2022.
Advances in cancer treatments have significantly improved their effectiveness, yet access to first-line therapies remains limited. A 2017 survey revealed that over 25 % of metastatic melanoma patients in Europe lacked access to recommended therapies. To address this, the European Association of Dermato-Oncology and the European Melanoma Registry conducted a follow-up study on the registration and reimbursement of first-line treatments.
View Article and Find Full Text PDFSarcoidosis-Like Reaction in Melanoma Patients Receiving Immunotherapy or Targeted Therapy.
Case Rep Oncol Med
December 2024
Oncology Unit Fondazione, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
This case series highlights the complexity of sarcoidosis-like reactions (SLRs) during cancer treatment, specifically in patients receiving immunotherapy or targeted therapies for melanoma. SLRs can either mimic disease progression or present as part of the clinical manifestation, making diagnosis and treatment challenging. Our study reviewed the medical records of 31 patients who were candidates for postoperative treatment between June 2022 and June 2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!